Amgen Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Amgen Inc (AMGN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Amgen Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 38,095M vs 643,406M combined for its competitors (5.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+5.6% annualized vs trailing 12 months), vs accelerating (+2.8%) for its tracked peer group.
- Growth: Amgen Inc generated 9.5% revenue growth year over year in Q2 2026, vs 13.2% for its competitors combined.
- Profitability: Its 23.6% net margin compares with 4.2% for the peer group.
- Scale: Amgen Inc ranks #1 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 26.2% of industry market cap.
- Peer revenue share: Amgen Inc accounted for 5.7% of combined revenue among its tracked peer group, down from 5.9% a year earlier.
- Peer differentiation: Revenue per employee of $2.93M compares with $0.86M for the peer group (3.4x).
- Structure: Amgen Inc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AMGN Sales vs. its Competitors, Q2 2026
Amgen Inc reported revenue growth of 9.53 % year on year in Q2 2026, below its competitors' combined revenue growth of 13.16 %.
With a net margin of 23.62 %, Amgen Inc achieved higher profitability than its competitors (4.20 %).
Amgen Inc generated 5.73 % of the combined sales of its peer group, down from 5.91 % a year earlier.
Amgen Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Amgen Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Amgen Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Amgen Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (52) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Amgen Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.8% year over year, combined, vs 9.5% for Amgen Inc. Amgen Inc's share of combined industry revenue moved from 24.64% to 22.34%, a loss of 2.30 percentage points.
Amgen Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Amgen Inc | Yes | Yes | Yes | No |
| Competitors combined (322) | ||||
| High-Confidence Competitors (72) | ||||
| Similar-Size Competitors (5) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AMGN Stock Performance relative to its Competitors
AMGN Stock Performance relative to High-Confidence Competitors
AMGN Stock Performance relative to Similar-Size Competitors
AMGN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Gt Biopharma Inc | 282.9% | Outperformed |
| 3 | Rockwell Medical inc | 282.9% | Outperformed |
| 4 | Kodiak Sciences Inc | 282.9% | Outperformed |
| 5 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Amgen Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Amgen Inc's Comment on Competition and Industry Peers
Certain of our marketed products face — and our product candidates, if
approved, are also expected to face — substantial competition. Our products’
competitive positions among other biological and pharmaceutical products may
be based on, among other things, safety, efficacy, reliability, availability,
patient convenience/delivery devices, price, reimbursement, timing of market
entry and patent position and expirations.
Certain of the existing patents on our principal products have recently expired
or will expire over the next few years, and we expect to face increasing competition
thereafter, including from biosimilars. A biosimilar is another version of a
biological product for which marketing approval is sought or has been obtained
based on a demonstration that it is “biosimilar” to the original
reference product. See Government Regulation. We may also compete against biosimilar
or generic versions of our competitors’ products. In the EU, we are facing
increasing competition from biosimilars. In the United States after patent expiration,
we expect to face greater competition than today, including from manufacturers
with biosimilars approved in Europe, which may seek to obtain U.S. approval.
Some of our products compete with each other. For example, Aranesp® and
EPOGEN® compete in the United States, primarily in the dialysis setting.
Neulasta® competes with NEUPOGEN®, as Neulasta® is administered
as a single dose per chemotherapy cycle while NEUPOGEN® requires more frequent
dosing. NEUPOGEN® sales have been adversely impacted by conversion to Neulasta®,
which we believe is substantially complete.
The introduction of new products, the development of new processes or technologies
by competitors or the emergence of new information about existing products may
result in increased competition for our marketed products, even for those protected
by patents, or in a reduction of the price that we receive from selling our
products. In addition, the development of new treatment options or standards
of care may reduce the use of our products or may limit the utility and application
of ongoing clinical trials for our product candidates. The following table reflects
our significant competitors and is not exhaustive.
Publicly Traded Peers of Amgen Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Amgen Inc |
260,293.12 | 38,095.00 |
 Eli Lilly And Company |
1,266,591.05 | 86,462.00 |
 Akari Therapeutics Plc |
1,103,252.65 | - |
 Johnson and Johnson |
676,597.15 | 99,335.00 |
 Beone Medicines Ltd |
568,695.62 | 6,128.24 |
 Abbvie Inc |
522,438.76 | 66,014.00 |
| SUBTOTAL | 6,884,926.52 | 808,223.87 |
Sign in to see all competitors of Amgen Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Amgen Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Amgen Inc's Competitors Named by the Company
Competitive relationships identified from Amgen Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Briacell Therapeutics Corp | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Zevra Therapeutics Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| G1 Therapeutics Inc | Company report | 85% |
| Adlai Nortye Ltd | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Cardiff Oncology Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Camp4 Therapeutics Corporation | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Vor Biopharma Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Altimmune inc | Company report | 85% |
| ADAPTIN BIO, INC. | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Generation Bio Co | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| Avastin | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| HUMIRA | Company report | 85% |
| Shuttle Pharmaceuticals Holdings Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Altamira Therapeutics Ltd | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Telomir Pharmaceuticals Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Sandoz Inc. | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Inflarx N V | Company report | 85% |
| Inmune Bio Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Immunitybio inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Jiayin Group Inc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| C4 Therapeutics Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Akebia Therapeutics Inc | Company report | 85% |
| Foghorn Therapeutics Inc | Company report | 85% |
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Dermata Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Immunovant Inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Alexion Pharmaceuticals Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Alvotech | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Kodiak Sciences Inc | Company report | 85% |
| Eqrx Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Apellis Pharmaceuticals Inc | Company report | 85% |
| Argenx Se | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Iteos Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Pfizer Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Amgen Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Amgen Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Amgen Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Amgen Inc | 260,293 | 2,930,385 | 672,538 |
| Eli Lilly And Company | 1,266,591 | 1,729,240 | 551,594 |
| Akari Therapeutics Plc | 1,103,253 | - | -4,674,667 |
| Johnson and Johnson | 676,597 | 705,504 | 114,311 |
| Beone Medicines Ltd | 568,696 | 510,686 | 54,642 |
| Abbvie Inc | 522,439 | 1,158,140 | 181,509 |
| PEERS TOTAL | 6,624,633 | 858,190 | 74,206 |
Amgen Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Amgen Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Amgen Inc's industry classification, broader than the peer set above. Market cap in millions of $.Amgen Inc ranks #1 of 158 companies by market capitalization in its industry, holding 26.21 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,370, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 260,293 | 26.21 % |
| 2 | Gilead Sciences Inc | 216,879 | 21.84 % |
| 3 | Moderna Inc | 102,835 | 10.35 % |
| 4 | Argenx Se | 61,498 | 6.19 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Mesoblast Limited | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Amgen Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-04.
Amgen Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Amgen Inc | 260,293 | 58.70 % |
| 2 | Gilead Sciences Inc | 216,879 | 40.41 % |
| 3 | Moderna Inc | 1,234 | 12.3% |
| 4 | Argenx Se | 1,234 | 12.3% |
| 5 | Revolution Medicines Inc | 1,234 | 12.3% |
| 6 | Biogen Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Amgen Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-04. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Amgen Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (158 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 69.52 % | 35.91 % (avg) | +33.6 pp |
| Operating Margin | 33.09 % | industry median | +33.6 pp |
| EBITDA Margin | 58.49 % | -2.95 % (avg) | +61.4 pp |
| Capital Intensity (Capex / Revenue) | 6.05 % | 8.17 % (avg) | -2.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Amgen Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (158 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 21.3x | 28.3x | -7.1x |
| EV / EBITDA | 10.4x | 17.6x | -7.2x |
| P/B | 19.0x | 5.2x | +13.8x |
| Return on Equity | 89.32 % | industry aggregate | 90.84 % |
| Return on Invested Capital | 16.45 % | -12.32 % (avg) | 28.77 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Amgen Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 3.93 % | -1.62 % | 8.83 % | 2.18 % | 1.32 % | 7.09 % | 18.57 % | 9.95 % |
| Operating Margin | 43.22 % | 41.41 % | 35.95 % | 29.40 % | 36.34 % | 28.01 % | 21.71 % | - |
| Return on Invested Capital | 14.54 % | 18.85 % | 14.57 % | 13.49 % | 19.43 % | 9.99 % | 9.77 % | - |
| P/E | 15.4x | 18.0x | 18.9x | 21.1x | 22.5x | 21.8x | 39.3x | 22.3x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Amgen Inc's Strategic Group Map
Amgen Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Amgen Inc's trailing-12-month revenue growth of 9.1% and operating margin of 33.1% compares with an average of 8.9% growth and 30.5% margin across its 8 closest peers by combined growth, margin and ROIC -- Amgen Inc sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Amgen Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Amgen Inc falls in the Cash Cow quadrant: relative market share of 1.20x vs its largest competitor, in an industry growing revenue 8.5% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Amgen Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,370 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 6.05 % vs industry average 8.17 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Amgen Inc's dedicated Suppliers and Customers pages, not here.
Amgen Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Amgen Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Amgen Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Market leader by capitalization in its industry (#1 of 158, 26.21 % share).
- Operating margin 33.6 points above the industry median.
- Return on equity 90.8 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+5.6% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- Trades at a lower P/E than the industry average (21.3x vs 28.3x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (47.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Losing revenue share to the broader industry (-2.3 points over the past year).
Methodology: see Methodology: SWOT Analysis.
Amgen Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Amgen Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| PEERS TOTAL | +9.3 % | -2.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Amgen Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
Amgen Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Amgen Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Amgen Inc | 29.72 | 6.83 |
| Eli Lilly And Company | 46.03 | 14.65 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 41.80 | 6.81 |
| Beone Medicines Ltd | 858.59 | 92.80 |
| Abbvie Inc | 50.75 | 7.91 |
| PEERS AVERAGE | 91.39 | 8.52 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.